- Active not recruitingPHASE1, PHASE2
Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)
This study is looking at new combinations of immunotherapy drugs for people with advanced lung cancer. It combines an existing drug, Cemiplimab, with one of three new drugs (S095018, S095024, or S095029) to see which combination is safe and works best.
For: Non-small Cell Lung Cancer (NSCLC)United States · Argentina · Australia - Active not recruitingPHASE1, PHASE2
A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.
This study looks at a new drug, S095029, combined with an existing treatment, pembrolizumab, for advanced stomach or gastroesophageal junction cancer. It aims to check safety and how well it works for specific types of cancer that have particular genetic markers.
For: MSI-H/dMMR Gastroesophageal-junction Cancer · MSI-H/dMMR Gastric CancerUnited States · Australia · Austria